LENZ Therapeutics: RSI Overbought, KDJ Death Cross on 15min Chart Triggered.

LENZ Therapeutics' 15-minute chart has recently displayed two technical indicators that suggest a potential shift in the stock's momentum. Firstly, the Relative Strength Index (RSI) has reached overbought levels, indicating that the stock price has risen too rapidly and is no longer supported by its underlying fundamentals. Secondly, the KDJ Death Cross has been triggered, which suggests that the momentum of the stock price is shifting towards the downside and has the potential to further decrease.

Title: LENZ Therapeutics Faces Technical Challenges Despite FDA Approval

LENZ Therapeutics' 15-minute chart has recently displayed two technical indicators that suggest a potential shift in the stock's momentum. Firstly, the Relative Strength Index (RSI) has reached overbought levels, indicating that the stock price has risen too rapidly and is no longer supported by its underlying fundamentals. Secondly, the KDJ Death Cross has been triggered, which suggests that the momentum of the stock price is shifting towards the downside and has the potential to further decrease.

The RSI is a momentum oscillator that measures the speed and change of price movements. An RSI over 70 is generally considered overbought, indicating that the stock may be due for a correction. Similarly, the KDJ Death Cross, a combination of the KDJ indicators, signals a potential reversal in the stock's trend. This bearish signal indicates that the stock price is likely to continue its downward trend [1].

Despite these negative technical signals, LENZ Therapeutics has recently received FDA approval for its aceclidine-based eye drop, LNZ100. This approval marks a significant milestone for the company, as it addresses presbyopia, the inevitable loss of near vision. The approval has lowered the risk of the investment and opened up new opportunities for the company, including partnerships with Lotus Pharmaceuticals and Laboratoires Théa for commercialization in various regions [1].

LENZ Therapeutics estimates a market size of $3B in the US alone, with a potential to capture 30% of this market. The company has a well-funded position, with over $200M in cash as of Q2 2025, providing a solid foundation for its growth plans. The company's sales team of over 100 members and direct-to-consumer strategies planned for Q1 2026 further support its growth prospects [1].

However, the technical indicators suggest a challenging period ahead. The MACD Death Cross and KDJ Death Cross are traditionally considered bearish signals, indicating a potential reversal in the stock's trend. Investors should closely monitor these indicators and consider the broader market conditions when making investment decisions [2].

References:
[1] https://www.ainvest.com/news/lenz-therapeutics-macd-death-cross-kdj-death-cross-triggered-15min-chart-2508/
[2] https://www.marketwatch.com/investing/stock/lenz